28.77

1.23% 0.35

After Hours: 28.50 -0.27 -0.94%

Agios Pharmaceuticals Inc (AGIO)

Overview News Price History Option Chain Financials Discussions Forecast

Agios Pharmaceuticals Inc stock is traded at $28.77, with a volume of 747.37K. It is up +1.23% in the last 24 hours and down -13.21% over the past month. Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236 and others.

Previous Close:

$28.42

Open:

$28.21

24h Volume:

747.37K

Relative Volume:

0.72

Market Cap:

$1.71B

Revenue:

$66.05M

Net Income/Loss:

$-422.60M

P/E Ratio:

-3.9677

EPS:

-7.251

Net Cash Flow:

$-384.73M

1W Performance:

+6.63%

1M Performance:

-13.21%

6M Performance:

-32.37%

1Y Performance:

+0.10%

1-Day Range:

$28.08

$28.87

1-Week Range:

$26.94

$29.01

52-Week Range:

$22.24

$46.00

Agios Pharmaceuticals Inc Stock (AGIO) Company Profile

Name

Agios Pharmaceuticals Inc

Sector

Healthcare (1106)

Industry

Biotechnology (616)

Phone

617-649-8600

Address

88 SIDNEY STREET, CAMBRIDGE, MA

Employee

540

Twitter

@AgiosPharma

Next Earnings Date

2026-04-29

Latest SEC Filings

AGIO's Discussions on Twitter

Compare AGIO vs VRTX, REGN, ARGX, ALNY, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
AGIO Agios Pharmaceuticals Inc	28.77	1.69B	66.05M	-422.60M	-384.73M	-7.251
VRTX Vertex Pharmaceuticals Inc	453.06	113.78B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	719.88	75.84B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	802.70	50.55B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	291.48	38.99B	4.29B	577.22M	641.34M	4.2086
ONC Beone Medicines Ltd Adr	316.55	32.69B	5.76B	514.49M	1.10B	4.4813

Agios Pharmaceuticals Inc Stock (AGIO) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Apr-20-26	Reiterated	H.C. Wainwright	Buy
Nov-24-25	Initiated	Truist	Buy
Nov-20-25	Upgrade	Leerink Partners	Market Perform → Outperform
Nov-19-25	Downgrade	RBC Capital Mkts	Outperform → Sector Perform
Feb-24-25	Initiated	H.C. Wainwright	Buy
Oct-16-24	Initiated	Scotiabank	Sector Outperform
Oct-10-24	Resumed	Raymond James	Outperform
Sep-27-24	Downgrade	Leerink Partners	Outperform → Market Perform
Feb-08-24	Initiated	Cantor Fitzgerald	Overweight
Feb-03-23	Initiated	Piper Sandler	Overweight
Nov-17-22	Upgrade	Goldman	Sell → Neutral
Jul-27-22	Upgrade	SVB Leerink	Mkt Perform → Outperform
Dec-03-21	Initiated	BofA Securities	Buy
Jul-30-21	Downgrade	Goldman	Neutral → Sell
Jul-01-21	Initiated	Raymond James	Mkt Perform
Jun-10-21	Initiated	H.C. Wainwright	Buy
Mar-01-21	Downgrade	JP Morgan	Overweight → Neutral
Mar-01-21	Upgrade	SVB Leerink	Mkt Perform → Outperform
Feb-26-21	Downgrade	SVB Leerink	Outperform → Mkt Perform
Oct-22-20	Upgrade	Barclays	Equal Weight → Overweight
Mar-04-20	Initiated	Barclays	Equal Weight
Nov-26-19	Initiated	Cantor Fitzgerald	Overweight
Sep-23-19	Upgrade	Guggenheim	Neutral → Buy
May-23-19	Resumed	Goldman	Neutral
Feb-15-19	Upgrade	SVB Leerink	Mkt Perform → Outperform
Sep-25-18	Initiated	Leerink Partners	Mkt Perform
May-23-18	Initiated	Citigroup	Buy
Apr-11-18	Reiterated	Credit Suisse	Outperform
Feb-15-18	Reiterated	Needham	Buy
Feb-15-18	Reiterated	SunTrust	Buy
Sep-15-17	Initiated	RBC Capital Mkts	Outperform
Aug-10-17	Reiterated	Needham	Buy
Aug-08-17	Reiterated	SunTrust	Buy
Aug-02-17	Upgrade	Leerink Partners	Mkt Perform → Outperform
Jun-26-17	Downgrade	Janney	Buy → Neutral
Jan-17-17	Upgrade	Oppenheimer	Perform → Outperform
Oct-24-16	Initiated	Needham	Buy
Jun-13-16	Upgrade	JP Morgan	Neutral → Overweight
May-18-16	Reiterated	SunTrust	Buy

View All

Agios Pharmaceuticals Inc Stock (AGIO) Latest News

03:19 AM

Agios sNDA And EHA Plenary Put Mitapivat At Center Of Valuation - Yahoo Finance

03:19 AM

11:21 AM

Agios Seeks FDA Nod to Expand Mitapivat Label in Sickle Cell Disease - Yahoo Finance

11:21 AM

May 12, 2026

Agios Pharmaceuticals (AGIO) Showcases Promising Mitapivat Data at EHA 2026 - GuruFocus

May 12, 2026

Agios presents mitapivat data at European hematology congress By Investing.com - Investing.com Australia

May 12, 2026

Agios presents mitapivat data at European hematology congress - Investing.com

May 12, 2026

Agios submits application for mitapivat in sickle cell disease - Investing.com

May 12, 2026

Agios Pharmaceuticals to Present RISE UP Phase 3 Trial Results of Mitapivat in Sickle Cell Disease at EHA 2026 Plenary Session - Quiver Quantitative

May 12, 2026

Agios submits application for mitapivat in sickle cell disease By Investing.com - Investing.com Canada

May 12, 2026

Agios Submits sNDA to FDA for U.S. Accelerated Approval of Mitapivat in Sickle Cell Disease - The Manila Times

May 12, 2026

Agios to Present New Data at EHA 2026 Reinforcing the Significant Therapeutic Impact of Mitapivat Across Multiple Rare Hemolytic Anemias - The Manila Times

May 12, 2026

New pill for sickle cell moves to FDA review, aims to cut transfusions - Stock Titan

May 12, 2026

Number of shareholders of Agios Pharmaceuticals, Inc. – TRADEGATE:8AP - TradingView

May 09, 2026

Agios plans Q2 sNDA filing for mitapivat in sickle cell disease while citing >$10B 2030 market opportunity - MSN

May 09, 2026

May 06, 2026

Lynx1 (AGIO) discloses 5.1% stake — 3.01M shares reported - Stock Titan

May 06, 2026

May 04, 2026

Need To Know: Analysts Are Much More Bullish On Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Revenues - 富途牛牛

May 04, 2026

May 03, 2026

Agios Pharmaceuticals Stock Rises 11.2% on Strong Q1 2026 Aqvesme Launch and Pipeline Progress - IndexBox

May 03, 2026

Agios Pharmaceuticals (AGIO) Is Up 11.2% After Rare Disease Launch And FDA Acceleration NewsHas The Bull Case Changed? - Sahm

May 03, 2026

May 02, 2026

Here's Why Shares in Agios Pharmaceuticals Soared This Week (And What to Expect Next in 2026) - Yahoo Finance

May 02, 2026

May 01, 2026

RBC Capital Sticks to Its Hold Rating for Agios Pharma (AGIO) - The Globe and Mail

May 01, 2026

MSN Money - MSN

May 01, 2026

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Q1 2026 Earnings Call Transcript - Insider Monkey

May 01, 2026

Agios Pharmaceuticals Hits Day High with 13.1% Surge in Stock Price - Markets Mojo

May 01, 2026

Apr 30, 2026

Agios Pharmaceuticals Reports 20.7 Million Dollars in Q1 Revenue - HarianBasis.co

Apr 30, 2026

AGIO Beats on Q1 Earnings & Sales, Stock Up 13% on New Drug Momentum - The Globe and Mail

Apr 30, 2026

Agios (AGIO) Q1 2026 Earnings Call Transcript - AOL.com

Apr 30, 2026

AGIO Maintained by Truist Securities -- Price Target Lowered to $36 - GuruFocus

Apr 30, 2026

Why Agios Pharmaceuticals Stock Zoomed to a 13% Gain on Wednesday - AOL.com

Apr 30, 2026

Truist Financial Issues Pessimistic Forecast for Agios Pharmaceuticals (NASDAQ:AGIO) Stock Price - MarketBeat

Apr 30, 2026

Agios Pharmaceuticals, Inc. Q1 2026 Earnings Call Summary - Yahoo Finance

Apr 30, 2026

(AGIO) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily

Apr 30, 2026